True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Brunelli, Matteo ^a   Bria, Emilio ^b   Nottegar, Alessia ^a   Cingarlini, Sara ^b   Simionato, Francesca ^b   Caliò, Anna ^a   Eccher, Albino ^a   Parolini, Claudia ^a   Iannucci, Antonio ^b   Gilioli, Eliana ^a   Pedron, Serena ^a   Massari, Francesco ^b   Tortora, Giampaolo ^b   Borze, Ioana ^c   Knuutila, Sakari ^c   Gobbo, Stefano ^a   Santo, Antonio ^a   Tondulli, Luca ^a   Calabrò, Francesco ^a   Martignoni, Guido ^a   Chilosi, Marco ^a   more..

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR SOX2;

ARTICLE; CHROMOSOMAL AMPLIFICATION; CHROMOSOME 3Q; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LUNG SQUAMOUS CELL CARCINOMA; PI3CA GENE; SOX2 GENE;

CARCINOMA, SQUAMOUS CELL; CHROMOSOME DUPLICATION; CHROMOSOMES, HUMAN, PAIR 3; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS;

EID: 84870845827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049689     Document Type: Article

References (41)

1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
2. Bria E, Gralla RJ, Raftopoulos H, Cuppone F, Milella M, et al. (2009) Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 63: 50-57.
3. Bria E, Milella M, Cuppone F, Novello S, Ceribelli A, et al. (2011) Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 22: 2277-2285.
4. Ciardiello F, Tortora G, (2008) EGFR antagonists in cancer treatment. N Engl J Med 358: 1160-1174.
5. Kettunen E, el-Rifai W, Bjorkqvist AM, Wolff H, Karjalainen A, et al. (2000) A broad amplification pattern at 3q in squamous cell lung cancer-a fluorescence in situ hybridization study. Cancer Genet Cytogenet 117: 66-70.
6. Qian J, Massion PP, (2008) Role of chromosome 3q amplification in lung cancer. J Thorac Oncol 3: 212-215.
7. Bjorkqvist AM, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Tammilehto L, et al. (1998) DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer 22: 79-82.
8. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, et al. (2010) Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 182: 83-91.
9. Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, et al. (2011) Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep 26: 877-885.
10. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, et al. (2011) Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer. Br J Cancer 104: 1410-1417.
11. Ambros IM, Benard J, Boavida M, Bown N, Caron H, et al. (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21: 2077-2084.
12. Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, et al. (2007) EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2: 423-429.
13. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, et al. (2009) EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 62: 970-977.
14. Horn L, Pao W, (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27: 4232-4235.
15. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
16. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, et al. (2009) SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 27: 4260-4267.
17. Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, et al. (2009) Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 341: 50-58.
18. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
19. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, et al. (2008) Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol 317: 296-309.
20. Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5: e8960.
21. Tompkins DH, Besnard V, Lange AW, Keiser AR, Wert SE, et al. (2011) Sox2 Activates Cell Proliferation and Differentiation in the Respiratory Epithelium. Am J Respir Cell Mol Biol.
22. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ, (2010) Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 70: 335-339.
23. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL, (2010) Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 34: 1193-1198.
24. Brunelli M, Eccher A, Gobbo S, Ficarra V, Novara G, et al. (2008) Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 21: 1-6.
25. Singh B, Gogineni SK, Sacks PG, Shaha AR, Shah JP, et al. (2001) Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res 61: 4506-4513.
26. Chujo M, Noguchi T, Miura T, Arinaga M, Uchida Y, et al. (2002) Comparative genomic hybridization analysis detected frequent overrepresentation of chromosome 3q in squamous cell carcinoma of the lung. Lung Cancer 38: 23-29.
27. Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, et al. (1997) Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res 57: 2116-2120.
28. Brass N, Ukena I, Remberger K, Mack U, Sybrecht GW, et al. (1996) DNA amplification on chromosome 3q26.1-q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting. Eur J Cancer 32A: 1205-1208.
29. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, et al. (1997) Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res 57: 2331-2335.
30. Bjorkqvist AM, Tammilehto L, Nordling S, Nurminen M, Anttila S, et al. (1998) Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77: 260-269.
31. Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, et al. (2001) Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer 31: 282-287.
32. Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, et al. (2002) Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 62: 3636-3640.
33. Yuan P, Kadara H, Behrens C, Tang X, Woods D, et al. (2010) Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5: e9112.
34. Yokoi S, Yasui K, Iizasa T, Imoto I, Fujisawa T, et al. (2003) TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancer Res 9: 4705-4713.
35. Racz A, Brass N, Heckel D, Pahl S, Remberger K, et al. (1999) Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma. Eur J Cancer 35: 641-646.
36. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, et al. (2011) SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 24: 944-953.
37. Hussenet T, du Manoir S (2010) SOX2 in squamous cell carcinoma: Amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle 9.
38. Brunelli M, Gobbo S, Cossu-Rocca P, Cheng L, Ficarra V, et al. (2008) Fluorescent cytogenetics of renal cell neoplasms. Pathologica 100: 454-460.
39. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, et al. (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A 102: 9625-30.
40. Pelosi G, Del Curto B, Trubia M, Nicholson AG, Manzotti M, et al. (2007) 3q26 Amplification and polysomy of chromosome 3 in squamous cell lesions of the lung: a fluorescence in situ hybridization study. Clin Cancer Res 13: 1995-2004.
41. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.